NeoSoma
- Company typePrivate
- Founded2017
- HeadquartersGroton, United States
- Headcount1–10
- GTM typeB2B
- OfferingSoftware
NeoSoma firmographics
Firmographics- Name
- NeoSoma
- Legal name
- Neosoma, Inc.
- Website
- https://neosomainc.com
- Company type
- Private
- Founded year
- 2017
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Ownership category
- akta.pro rank
NeoSoma industry classification
Industry- Product category
- AI Neuro-Oncology Imaging Software
- SIC
- Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- SaMD – Imaging & Signal Analysis (AI/ML) (HLACANAG)
- akta.pro secondary industries
- Neuro-Oncology (HLAKAFAH), Medical Imaging AI (HDAAAEAH)
Keywords
Where NeoSoma is headquartered
LocationHeadquarters
- HQ city
- Groton
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
NeoSoma business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
Revenue model
- Per-MRI Analysis Reimbursement: Revenue generated through Category 3 CPT codes 0865T and 0866T, which allow providers to submit claims for Neosoma's MRI analysis service on a per-MRI-analysis basis, with or without a same-session diagnostic MRI. The software platform is priced based on MRI volume, allowing multiple team members to have logins without incremental seat license costs.
- Platform Subscription/Usage: Cloud-based SaaS model where Neosoma's solution is priced based on MRI volume, supporting unlimited multidisciplinary team members with logins to foster adoption and usage without per-seat licensing costs.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Usage-based | Monthly | MRI Volume-Based Pricing |
Go-to-market motion1 record
Distribution channels1 record
Marketing channels5 records
NeoSoma product offering
Product offeringCore offering
NeoSoma develops FDA-cleared AI software medical devices that analyze brain MRI scans for neuro-oncology clinicians. Its cloud platform performs 3D tumor mapping, longitudinal lesion tracking, volumetric quantification, and automated GTV auto-contouring for gliomas and brain metastases. The platform serves multidisciplinary clinical teams, researchers, and clinical trial sponsors, integrating with major treatment planning systems and leveraging Category 3 CPT codes (0865T and 0866T) for per-MRI-analysis reimbursement.
Product overview
Neosoma offers a cloud-based SaaS platform with two FDA-cleared indication-specific software medical devices. The Neosoma Platform serves as the core infrastructure providing lesion mapping, measuring, tracking, and consolidation of longitudinal lesion data for the multidisciplinary neuro-oncology team. Neosoma Glioma supports high-grade and low-grade glioma analysis and auto-contouring, while Neosoma Brain Mets provides metastatic brain lesion assessment with lesion-level quantification and tracking. Both products are fully integrated into the Neosoma cloud platform, interoperable with treatment planning systems, and reimbursable under Category 3 CPT codes.
Differentiator
Problem solved
Functional benefit
Brands
- Neosoma Platform: Proprietary cloud platform for tumor analysis, mapping, measuring, tracking, and consolidating longitudinal lesion data for neuro-oncology teams.
- Neosoma Glioma
- Neosoma Brain Mets
Products and services
- Neosoma Platform Cloud-based SaaS platform purpose-built for the multidisciplinary neuro-oncology clinical team, researchers, and clinical trials. Maps and measures tumor compartments, tracks lesions longitudinally, and delivers key insights in near-real-time, with interoperability to radiation treatment and surgical planning systems.
- Neosoma Glioma FDA-cleared AI software for high-grade and low-grade glioma longitudinal analysis and auto-contouring. Automatically quantifies enhancing tissue, T2/FLAIR hyperintensity, and necrosis plus cavity from standard MRI sequences at the voxel level; supports GTV contouring for radiation treatment and surgical planning.
- Neosoma Brain Mets FDA-cleared AI software for efficient assessment and auto-contouring of metastatic brain lesions. Quantifies and measures total tumor burden and each individual lesion at each timepoint on routinely-acquired T1 post-contrast MRI sequences with near-real-time processing and human expert-level performance.
Quantifiable outcome
- Reduces segmentation time by over 90% (pre-operative: 210.5s, post-operative: 179s vs. 15s with Neosoma HGG)
- +1 more outcomes
Companies that use NeoSoma
Customer profileNamed customers6 records
Segments3 records
Ideal customer profiles3 records
NeoSoma technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration6 records
AI capability3 records
Feature5 records
NeoSoma partnerships and signals
Strategic signalPartnerships
Five partnerships are on record, tiered minor and core.
- InnoliticsminorInnolitics published a case study highlighting their collaboration with Neosoma, showcasing the partnership in advancing medical imaging analysis capabilities.
- Inselspital (Bern University Hospital)coreCollaboration with Inselspital Department of Radiation Oncology, led by Prof. Dr. med. Daniel M. Aebersold, deploying Neosoma's glioma, brain metastases, and brain organs at risk AI-based software to support clinical research efforts. The collaboration has already produced research on high-grade glioma auto-contouring capabilities and radiation treatment planning workflows.
- Hackensack Meridian HealthcoreStrategic partnership for brain tumor treatment and research. The collaboration includes clinical data sharing, clinical research, and strategic investment from the health network. HMH physicians will use Neosoma's software in clinical practice starting with Hackensack Meridian JFK University Medical Center, with physician input for future software development.
- CalyxcoreStrategic partnership for AI-powered neuro-oncology clinical trials. Calyx provides eClinical and regulatory solutions for oncology trials with nearly 100 neuro-oncology clinical trials supported. Neosoma's software provides accurate 3D longitudinal tumor measurements to address variability in manual 2D measurements that can lead to inconsistent clinical trial results.
- Nuance CommunicationscoreNeosoma's AI solutions connect to the Nuance Precision Imaging Network. Nuance is a leading radiology software solutions provider with nationwide scale of its PowerScribe and PowerShare diagnostic imaging solutions. The partnership enables more efficient implementation of Neosoma's software platform across thousands of sites.
Scale indicators4 records
Recent moves6 records
Expansion highlights6 records
NeoSoma competitors and assessment
Company assessmentDirect peers
- Annalise.ai: Annalise.ai develops comprehensive AI models for radiology imaging and integrates them into clinical workflow, including oncology findings. Comparable to Neosoma as a multi-indication AI imaging SaaS targeting hospital and clinical-trial use cases.
- icometrix: icometrix builds AI-based software for brain MRI quantification (multiple sclerosis, dementia, traumatic brain injury), making it a direct peer in brain-imaging AI SaaS sold to clinical sites and clinical trials. It shares Neosoma's MRI-based volumetric analysis model and clinical-trial/sponsor channel.
- RapidAI: RapidAI sells AI imaging software into hospital stroke and imaging workflows with a SaaS business model, FDA clearances, and reimbursement-aligned economics — closely mirroring Neosoma's commercialization playbook in a different neuro indication.
- Subtle Medical: Subtle Medical provides AI-powered medical imaging software that integrates into MRI workflows and is sold to hospitals and imaging centers. Comparable as an AI imaging SaaS vendor monetizing through hospital imaging volume.
- Aidence: Aidence (Veye Lung Nodules) is an oncology-focused AI imaging company selling FDA/CE-cleared clinical decision support into hospital radiology — comparable to Neosoma in regulatory path, indication-specific AI imaging, and hospital SaaS model.
- Viz.ai: Viz.ai provides FDA-cleared, reimbursed AI imaging software deployed in hospital systems to triage and coordinate neuro patients. It is a direct analogue for Neosoma's enterprise SaaS go-to-market, clinical workflow integration, and Category III CPT-style monetization.
Emerging players
- Paige.AI: Paige.AI builds FDA-authorized AI for cancer pathology and imaging, with both clinical and biopharma channels — overlapping with Neosoma's clinical trial (Calyx) and oncology AI strategy, though in pathology rather than radiology.
Broad incumbents
- Siemens Healthineers (AI-Rad Companion): Siemens Healthineers ships AI-Rad Companion and similar imaging AI suites embedded in its radiology modality fleet. Represents the incumbent bundling risk Neosoma faces from large imaging vendors offering AI features as part of broader enterprise deals.
- Philips (IntelliSpace AI): Philips offers a broad portfolio of radiology AI and treatment-planning software integrated into its imaging and oncology systems. It is a broad incumbent competitor that could bundle neuro-oncology AI capabilities into its enterprise platform.
- Brainlab: Brainlab is both a current Neosoma integration partner and a broad incumbent in radiation oncology and neurosurgery treatment planning. Its portfolio includes AI-driven auto-contouring and surgical planning that competes with Neosoma's GTV auto-contouring capability.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks7 records
Key highlights7 records
Customer concentration
NeoSoma social profiles
Digital presenceNeoSoma compliance and trust
Trust signalCompliance1 record
NeoSoma financial estimates
Financial estimateRevenue estimate
Valuation estimate
NeoSoma leadership team
Management profileNumber of profiles
Profiles19 records
NeoSoma subsidiaries and ownership
Company hierarchySubsidiaries1 record
NeoSoma funding detail
Funding detailFunding overview
Funding rounds2 records
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
NeoSoma M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about NeoSoma
What does NeoSoma do?
NeoSoma develops FDA-cleared AI software medical devices that analyze brain MRI scans for neuro-oncology clinicians. Its cloud platform performs 3D tumor mapping, longitudinal lesion tracking, volumetric quantification, and automated GTV auto-contouring for gliomas and brain metastases. The platform serves multidisciplinary clinical teams, researchers, and clinical trial sponsors, integrating with major treatment planning systems and leveraging Category 3 CPT codes (0865T and 0866T) for per-MRI-analysis reimbursement.
Is NeoSoma a public or private company?
NeoSoma is a private company. It is classified as venture growth investor backed and is currently operating.
When was NeoSoma founded?
NeoSoma was founded in 2017. It employs 1 to 10 people.
Where is NeoSoma based?
NeoSoma is headquartered in Groton, United States, in the North America region.
How does NeoSoma make money?
Two revenue lines are on record. Per-MRI Analysis Reimbursement is the primary driver. The others are platform Subscription/Usage.
Who are NeoSoma's main competitors?
Direct peers on record are Annalise.ai, icometrix, RapidAI, Subtle Medical, Aidence and Viz.ai. Paige.AI is listed as an emerging player. Broad incumbents are Siemens Healthineers (AI-Rad Companion), Philips (IntelliSpace AI) and Brainlab.
Does NeoSoma have an API?
No public API is recorded for NeoSoma.
What industry is NeoSoma in?
NeoSoma's product category is AI Neuro-Oncology Imaging Software. Its primary akta.pro industry code is HLACANAG, SaMD – Imaging & Signal Analysis (AI/ML), with a secondary code of HLAKAFAH, Neuro-Oncology. Its SIC code is 3841.